Design of Trials to Assess Safety and Effectiveness in Rx of CHF
It is a propitious time to consider drugs for the treatment of congestive heart failure (CHF). There is at present a great deal of academic and commercial interest in such agents, perhaps reflecting an early success, Captopril, and a partial success, amrinone IV, after a good deal of ambiguity and failure with prazosin and the beta agonists. Yet there is still a great deal to be learned. We do not yet know how much it is possible to achieve or what hemodynamic or exercise responses to drugs correspond best to clinically meaningful improvement.
KeywordsCongestive Heart Failure Exercise Tolerance Filling Pressure Beta Agonist Vasospastic Angina
Unable to display preview. Download preview PDF.